BACKGROUND: The effect of bosentan on the ventricular and atrial performance in patients with Eisenmenger syndrome is unclear. In adult patients with Eisenmenger syndrome, we aimed to evaluate the midterm effect of bosentan on physical exercise, ventricular and atrial function, and pulmonary hemodynamics. METHODS: Forty adult patients before and after 24 weeks bosentan therapy underwent 6 min walk test, two-dimensional speckle tracking echocardiography, plasma NT-proBNP measurement and cardiac catheterization. RESULTS: After 24 weeks, bosentan therapy an improvement was observed regarding the 6 min walk distance from a median (quartile 1-quartile 3) of 382.5 (312-430) to 450 (390-510) m (p = 0.0001), NT-proBNP from 527.5 (201-1,691.25) to 369 (179-1,246) pg/ml (p = 0.021), right ventricular mean longitudinal systolic strain from 18 (13-22) to 19 (14.5-25) % (p = 0.004), left ventricular mean longitudinal systolic strain from 16 (12-21) to 17 (16-22) % (p = 0.001), right atrial mean peak longitudinal strain from 26 (18-34) to 28 (22-34) % (p = 0.01) and right atrial mean peak contraction strain from 11 (8-16) to 13 (11-16) % (p = 0.005). The invasively obtained Qp:Qs and Rp:Rs did not significantly change under bosentan therapy. CONCLUSIONS: In adult patients with Eisenmenger syndrome, bosentan therapy improves ventricular and atrial functions resulting in enhancement of physical exercise and reduction in the NT-proBNP level, while the pulmonary vascular resistance does not change substantially.
BACKGROUND: The effect of bosentan on the ventricular and atrial performance in patients with Eisenmenger syndrome is unclear. In adult patients with Eisenmenger syndrome, we aimed to evaluate the midterm effect of bosentan on physical exercise, ventricular and atrial function, and pulmonary hemodynamics. METHODS: Forty adult patients before and after 24 weeks bosentan therapy underwent 6 min walk test, two-dimensional speckle tracking echocardiography, plasma NT-proBNP measurement and cardiac catheterization. RESULTS: After 24 weeks, bosentan therapy an improvement was observed regarding the 6 min walk distance from a median (quartile 1-quartile 3) of 382.5 (312-430) to 450 (390-510) m (p = 0.0001), NT-proBNP from 527.5 (201-1,691.25) to 369 (179-1,246) pg/ml (p = 0.021), right ventricular mean longitudinal systolic strain from 18 (13-22) to 19 (14.5-25) % (p = 0.004), left ventricular mean longitudinal systolic strain from 16 (12-21) to 17 (16-22) % (p = 0.001), right atrial mean peak longitudinal strain from 26 (18-34) to 28 (22-34) % (p = 0.01) and right atrial mean peak contraction strain from 11 (8-16) to 13 (11-16) % (p = 0.005). The invasively obtained Qp:Qs and Rp:Rs did not significantly change under bosentan therapy. CONCLUSIONS: In adult patients with Eisenmenger syndrome, bosentan therapy improves ventricular and atrial functions resulting in enhancement of physical exercise and reduction in the NT-proBNP level, while the pulmonary vascular resistance does not change substantially.
Authors: Ingram Schulze-Neick; Nadine Gilbert; Ralf Ewert; Christian Witt; Ekkehard Gruenig; Beate Enke; Mathias M Borst; Peter E Lange; Marius M Hoeper Journal: Am Heart J Date: 2005-10 Impact factor: 4.749
Authors: Martin Koestenberger; Bert Nagel; William Ravekes; Allen D Everett; Hans Peter Stueger; Bernd Heinzl; Erich Sorantin; Gerhard Cvirn; Andreas Gamillscheg Journal: Clin Res Cardiol Date: 2010-09-12 Impact factor: 5.460
Authors: Karola Trescher; Michael Bauer; Wolfgang Dietl; Seth Hallström; Nikolaus Wick; Margarita Wolfsberger; Robert Ullrich; Günther Jürgens; Ernst Wolner; Bruno K Podesser Journal: J Thorac Cardiovasc Surg Date: 2009-02-12 Impact factor: 5.209
Authors: James E Sharman; Joseph Brown; David J Holland; Graeme Macdonald; Karam Kostner; Thomas H Marwick Journal: Hypertension Date: 2009-08-31 Impact factor: 10.190
Authors: Giorgio Serino; Marco Guazzi; Angelo Micheletti; Carlo Lombardi; Rossella Danesi; Diana Negura; Mario Carminati; Massimo Chessa Journal: Clin Med Insights Cardiol Date: 2013-02-06